



UNITED STATES PATENT AND TRADEMARK OFFICE

OB
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/705,448	11/11/2003	Joseph L. Witztum	6627-P0045C	4879
41790	7590	09/25/2006		EXAMINER
				COOK, LISA V
			ART UNIT	PAPER NUMBER
				1641

DATE MAILED: 09/25/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Applicant No.	Applicant(s)
	10/705,448	WITZTUM ET AL.
	Examiner Lisa V. Cook	Art Unit 1641

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 07 July 2006.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 27-45 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 27,30-42,44 and 45 is/are rejected.
- 7) Claim(s) 28,29 and 43 is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>7/7/06</u> .	6) <input type="checkbox"/> Other: _____.

DETAILED ACTION

Amendment Entry

1. Applicants' response to the Office Action mailed 12/29/05 is acknowledged (paper filed 7/7/06). In the amendment filed 7/7/06 the specification along with claims 27, 34, 35, and 36 were modified. Claims 1-26 were previously cancelled. Accordingly, claims 27-45 are pending and under consideration.
2. Objections and/or rejections of record not reiterated herein have been withdrawn.

OBJECTIONS WITHDRAWN

Information Disclosure Statement

3. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609 A(1) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the Examiner on form PTO-892 or Applicant on form PTO-1449 has cited the references they have not been considered. See pages 19 and 20.
4. The Information Disclosure Statements filed 11/11/03 and 3/29/04 were considered as to the merits prior to First Action.
5. The Information Disclosure Statement filed 7/7/06 has been considered as to the merits before Final Action.

REJECTIONS WITHDRAWN

*Double Patenting*6. Double patenting obviousness-type rejection:

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 27-45 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-19 of US Patent No. 6,716,410.

Although the conflicting claims are not identical, they are not patentably distinct from each other because both claims are drawn to the imaging of atherosclerotic plaque in a host via monoclonal antibodies specific for oxidation specific epitopes. Both methods employ IK17 comprising SEQ ID NO:1 and SEQ ID NO:2. The instant method is encompassed in US Patent #6,716,410.

Response to Arguments

Applicants have filed a Terminal Disclosure (TD) over US Patent #6,716,410. The TD has been approved. Accordingly the ODP in item 7 above have been withdrawn.

REJECTIONS MAINTAINED

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claims 27, 30-42, and 44-45 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. In particular, claim 27 is drawn to a method employing an antibody recognition site having the following properties: (i) the antibody is specific for oxidation specific epitopes present in the core of atherosclerotic plaques; and (ii) the antibody is specific for oxidized low density lipoprotein and malondialdehyde low density lipoprotein.

Further, it is not known how the monoclonal antibody having single binding specificity will bind both oxidized low-density lipoprotein and malondialdehyde low-density lipoprotein simultaneously. The claims and specification fail to provide the identity or structure of this antibody recognition site. The specification does not provide evidence of a nucleic acid sequence, other than the sequence of SEQ ID NO: 1 and SEQ ID NO: 2 which are known in the art. From these known sequences primers are produced with the claimed inventive properties allowing for detection in the instantly claimed method; however the specification does not state the identity to a deposited antibody, amino acid sequence, nucleic acid sequence, or any structural characteristics of any other antibody, amino acid sequence, or nucleic acid sequence that has the claimed characteristics.

Moreover, there is evidence that other sequences have not yet been identified therefore; applicants' vague description of an isolated nucleic acid sequence (primers from SEQ ID NO: 1 and SEQ ID NO: 2) has not been adequately described. In view of the lack of evidence, it is apparent that Applicants were not in possession of the unlimited number of primers which may be produced from the known sequences of SEQ ID NO: 1 and SEQ ID NO: 2, at the time of filing the instant application. The skilled artisan cannot envision the detailed structure of the infinite possible antibodies, amino acid sequences, or isolated nucleic acid sequences, thus conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. An adequate description requires more than a mere statement that it is part of the invention. The nucleic acid structure is required. See *Fiers v. Revel*, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Lts.*, 18 USPQ2d 1016.

The antibody activity characteristics and tail domain requirements distinguish the antibody only by what it does, i.e., protein activity, which are purely functional distinctions. Even where there is an actual reduction to practice, which may demonstrate possession of an embodiment of an invention, it does not necessarily describe what the claimed invention is. The instant specification and claims describe an isolated monoclonal antibody by its protein function, however this description does not describe the claimed antibody itself. See also, *In The Reagents of the University of California v. Eli Lilly* (43 USPQ2d 1398-1412), where the court held that a generic statement which defines a genus of a compound/seq.id/etc. by only their functional activity does not provide an adequate written description of the genus. The court indicated that while Applicants are not required to disclose every species encompassed by a genus, the description of a genus is achieved by the recitation of a representative number of molecules, usually defined by a sequence, falling within the scope of the claimed genus. At section B(1), the court states that "An adequate written description ...'requires a precise definition, such as by structure, formula, chemical name, or physical properties', not a mere wish or plan for obtaining the claimed chemical invention".

Thus a skilled artisan cannot envision all the contemplated recognition sequence sites by the detailed chemical structure of the claimed antibody, therefore conception cannot be achieved until reduction to practice has occurred. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Art Unit: 1641

Applicant does not provide guidance for the above noted monoclonal antibodies and provides no guidance as to what modifications or structure are important for the predictable function of the monospecific antibody. Very different structures may be found on antibodies with the same specificity. For example, very different V_H chains can combine with the same V_L chain to produce antibody binding sites with nearly the same size, shape, antigen specificity, and affinity.

A similar phenomenon can also occur when different V_H sequences combine with different V_L sequences to produce antibodies with very similar properties. These observations indicate that divergent variable region sequences, both in and out of complementarily determining regions, can be folded to form similar binding site contours, which result in similar immunochemical characteristics. Conversely, similar structure may be found on antibodies having different specificities.

Response to Arguments

Applicants have argued that the recent court decision of *Noelle v. Lederman*, 355 F.3d 1343 (Fed. Cir. 2004). In *Noelle*, claims which recite a genus of antibodies that bound to a mouse antigen were found to be unpatentable, because the corresponding human antigen had not been adequately characterized. This is the same issue currently at hand. Applicant's claims are not merely directed to antibodies for the known antigen described in the specification, the IK17- (SEQ ID NO: 1 and SEQ ID NO: 2) but reads on a infinite possibility of unknown antigens. The claims are drawn to fragments thereof and small molecule analogs. These antigens are not all well known and characterized, therefore the rejection is maintained.

Please Note: The rejections maintained below are presented with respect to the claimed invention reading on “fragments thereof” and “small molecule analog” wherein the required similarity with respect to the claimed antibodies has not been defined. Therefore antibodies binding having a single similar characteristic of the binding Cu-OxLDL and MDA-LDL, appear to read on the claims.

Double Patenting

9. Double patenting obviousness-type rejection:

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

10. Claims 27 and 35 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7 of US Patent No. 6,375,925. Although the conflicting claims are not identical, they are not patentably distinct from each other because both claims are drawn to the imaging of atheroscleotic plaque in a host via monoclonal antibodies specific for oxidation specific epitopes.

US Patent #6,375,925 differs from the instant invention in using monoclonal antibodies MDA2 and NA59. However the instant claims are drawn to any detectably labeled human or humanized Mab or fragment thereof, Fab, scFv, or small molecule analog with specific epitopes present in the core of atherosclerotic plaques. Thus it would have been obvious to one of ordinary skill in the art that the instant invention is encompassed within the claims of US Patent #6,375,925.

11. Claims 31 and 32 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7 of US Patent No. 6,375,925 in view of Tsimiksa et al. (Journal of Nuclear Cardiology, Volume 6, Number 1, pages 41-53, January/February 1999, Part I).

Although the conflicting claims are not identical, they are not patentably distinct from each other because both claims are drawn to the imaging of atheroscleotic plaque in a host via monoclonal antibodies specific for oxidation specific epitopes.

US Patent #6,375,925 differs from the instant invention from the instant invention in not specifically teaching imaging procedures that include a correlation between another site in the body not having atherosclerotic plaques (claim 32) and progression or regression of atherosclerotic disease (claim 31).

However, Tsimikas et al. describe these limitations in their method utilizing radio labeled MDA2 (an oxidation-specific monoclonal antibody for atherosclerotic lesions). The method evaluates atherosclerotic arteries and normal arteries for the pathogenesis (pathology) and adverse consequences of atherosclerotic lesions (aortic plaques). See abstract and figures 3 & 4. All the results were compared with normal aortas of NZW rabbits and normal adjacent tissue in the same rabbits (page 50, 2nd column, 1st paragraph).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to employ normal tissue comparison techniques (claim 4) to study disease progression or regression (claim 5) as taught by Tsimikas et al. in the US Patent 6,375,925 to perform atherosclerotic plaque imaging analysis, because Tsimikas et al. taught that these protocols “provide a means to non-invasively detect, quantify, and follow the natural history of human atherosclerotic lesions”. Page 52, 1st column, last sentence.

Response to Arguments

Applicants contends that the ‘925 patent is directed towards the production of antibodies that are specific for a single epitope on an oxLDL and not antibodies that cross reacts with two or more epitopes. This argument was carefully considered but not found persuasive because the claims read on fragments thereof or small molecule analogs which do not require cross reactivity of two or more epitopes. The rejections are maintained.

Claim Rejections - 35 USC § 102

12. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

I. Claims 27, 31, and 34-35 are rejected under 35 U.S.C. 102(e) as being anticipated by Witztum et al. (US Patent #6,225,070)

Witztum et al. disclose monoclonal antibodies that specifically bind oxidation-specific epitopes on lipoprotein in blood, arterial tissue and vascular tissue, including atherosclerotic plaque formed in arterial tissue and vascular tissue. See abstract. Several monoclonal antibodies are disclosed (See tables I and II). E06, E013, E014, and E017 were shown to bind MDA-LDL and oxLDL (Cu 2+ oxidized LDL) – meeting the antibody requirement found on page 4, lines 22-24 of the instant disclosure. The labeled antibodies were employed to image *in vivo* atherosclerotic plaque (column 10, section B).

Various detection procedures are given in column 10, lines 37-53.. (therein meeting the limitations of claims 8 and 9). The antibodies are delivery dosage to the host ranges and is dependent on the desired effect (column 14, lines 18-31).

Response to Arguments

Applicant contends that the antibodies taught in US Patent #6,225,070 do not anticipate the instant invention because the antibodies exhibit differential binding to LDL associated epitopes, but none are selected to be specific for MDL-LDL and Cu-OxLDL and any cross-reactivity between the antibodies is merely incidental. This argument was carefully considered but not found persuasive because the claims are directed to the utility of antibodies, fragments, or analogues that are specific for MDL-LDL and Cu-OxLDL but do not bind native LDL. US Patent #6,225,070 discloses antibodies that appear recognize (bind) both MDL-LDL and Cu-OxLDL and not native LDL. See for example US Patent #6,225,070; figure 3 and column 3 lines 14-28. Antibodies E05, E011, E014, E017, and MDA2 do not bind native LDL (see line 6 on figure 3) but bind to both MDA-LDL (see lines 2-5 and 7-9 on figure 3) and CuOx-LDL (see lines 10-14 and lines 15-20 on figure 3). With respect to the degree of binding it is noted that neither the claims nor the specification require specific binding/non-binding measurements (eliminating cross reactivity) to read over the cited prior art.

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., cross-reactive antibody binding) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

In response to the argument that the antibodies were not selected for use in the method of imaging atherosclerotic plaques because they recognized both MDA-LDL and Cu-OxLDL, it is noted that the '070 patent uses the antibodies to monitor atherosclerotic plaques (see column 1 line 48 through column 2 line 46, for example) and this is what the instant claims recite. See column 10 line 26 through column 11 line 54.

With respect to the inhibition of Cu-OxLDL uptake by macrophages, it is noted that this is deemed inherent to the antibodies that bind Cu-OxLDL. US Patent #6,225,070 teaches that OxLDL becomes incorporated into plaque lesions during atherogenesis....and becomes oxidatively modified by various cell types including macrophages. See column 4 lines 32-42. The '070 patent further teaches that the antibodies are useful in defining epitopes and screening for agents to inhibit oxidation-specific LDL epitope binding by macrophages. See column 13 lines 21-26.

Claim Rejections - 35 USC § 103

13. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1641

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

II. Claims 30-32 and 38-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Witztum et al. (US Patent #6,225,070) in view of Tsimiksa et al. (Journal of Nuclear Cardiology, Volume 6, Number1, pages 41-53, January/February 1999, Part I).

Please see Witztum et al. as set forth above.

Witztum et al. differ from the instant invention in not specifically teaching imaging procedures that include a correlation between another site in the body not having atherosclerotic plaques and pathology evaluations of the atherosclerotic plaques.

However, Tsimikas et al. describe these limitations in their method utilizing radio labeled MDA2 (an oxidation-specific monoclonal antibody for atherosclerotic lesions). The method evaluates atherosclerotic arteries and normal arteries for the pathogenesis (pathology) and adverse consequences of atherosclerotic lesions (aortic plaques). See abstract and figures 3 & 4. All the results were compared with normal aortas of NZW rabbits and normal adjacent tissue in the same rabbits (page 50, 2nd column, 1st paragraph).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to employ normal tissue comparison techniques to study relative pathology as taught by Tsimikas et al. in the method Witztum et al., to perform atherosclerotic plaque imaging analysis, because Tsimikas et al. taught that these protocols “provide a means to non-invasively detect, quantify, and follow the natural history of human atherosclerotic lesions”. Page 52, 1st column, last sentence.

One having ordinary skill in the art would have been motivated to do this to acquire the enhanced sensitivity and ability to reduce background fluorescence while providing more data sets for analysis, wherein accurate and precise detection is rapidly available.

III. Claims 36 is rejected under 35 U.S.C. 103(a) as being unpatentable over Witztum et al. (US Patent #6,225,070) in view of Fuster et al. (Circulation, 1900, 82(3) Suppl. Pages II-47-II59, Abstract Only).

Please see Witztum et al. as set forth above.

Witztum et al. differ from the instant invention in not specifically teaching lipid pool percentages of the plaque area.

However, Fuster et al. teach that plaques with increased lipid content appear more prone to rupture, particularly in lipid pools localized within the intima. Rupturing of an atherosclerotic plaque associated with partial or complete thrombotic vessel occlusion is fundamental to the development of ischemic coronary syndromes. See abstract.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to detect plaques containing excess lipid pools (exceeding 40% of the plaque area) as taught by Fuster et al. in the method of Witztum et al. performing atherosclerotic plaque imaging analysis, because Fuster et al. taught that plaques with increased lipid content appear more prone to rupture and rupturing of an atherosclerotic plaque associated with partial or complete thrombotic vessel occlusion is fundamental to the development of ischemic coronary syndromes.

See abstract.

One having ordinary skill in the art would have been motivated to do identify, locate and treat these plaques before they rupture and cause further damage like coronary syndrome.

IV. Claims 33, 34, 37, and 44-45 are rejected under 35 U.S.C. 103(a) as being unpatentable over Witztum et al. (US Patent #6,225,070) in view of Tsimiksa et al. (WO 98/21581).

Please see Witztum et al. as set forth above.

Witztum et al. differ from the instant invention in not specifically teaching imaging procedures that include the administration of an antigen to reduce residual label.

However, Tsimikas et al. describe these limitations in their method for in vivo diagnosis of atherosclerosis. (see abstract) In this method an epitope antigen monoclonal antibody imaging agent is coupled to a protein carrier and injected into the blood stream of the patient after injection of the imaging antibody to maximize removal of residual imaging antibody from the plasma (page 18 line 23- page 19, line 3).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to administer an antigen or related labeled antibody to the host after the introduction of the detectable labeled antibody as taught by Tsimikas et al. in the method Witztum et al., to perform atherosclerotic plaque imaging analysis, because Tsimikas et al. taught that this advantage substantially enhanced the target-to-background ratio for detection of antibody binding to plaque (page 19, lines 4-11).

Response to Arguments

Applicant argues that the '070 patent does not teach or suggest every limitation of claim 27, namely all the combined characteristics recite in the instant claims, therefore the combination of references under 35 USC 103(a) cannot be obvious. This argument was carefully considered but not found persuasive because the '070 patent has been addressed above. Therefore the rejections are maintained.

Allowable Subject Matter

14. Claims 28, 29 and 43 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

15. For reasons aforementioned, no claims are allowed.

Art Unit: 1641

16. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Remarks

17. Prior art made of record and not relied upon is considered pertinent to the applicant's disclosure:

A. Selle et al. (WO 94/23302) teach an immunological ELISA assay-employing antibodies to measure oxidatively modified human low-density lipoproteins in plasma samples.

B. Holvoet et al. (Journal of Clinical Investigation, Vol.95., No.6., 1 June 1995, pages 2611-2619) disclose a method for detecting MDA-modified LDL. A monoclonal antibody (mAb-1H11) which to bind with MDA-modified LDL ($ka=10^9 M^{-1}$) and to a much lesser extent with OxLDL (page 2613, column 2, paragraph 1) is described in an immunoassay format.

18. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Group 1641 – Central Fax number is (571) 273-8300, which is able to receive transmissions 24 hours/day, 7 days/week. In the event Applicant would like to fax an unofficial communication, the Examiner should be contacted for the appropriate Right Fax number.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa V. Cook whose telephone number is (571) 272-0816. The examiner can normally be reached on Monday - Friday from 7:00 AM - 4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, can be reached on (571) 272-0823.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group TC 1600 whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Lisa V. Cook

Remsen 3C-59

(571) 272-0816

9/15/06



LONG V. LE 09/18/06

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600